Drug Trial Radar · NCT06136741
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
396
Planned (sponsor's estimate)
Start
Nov 15, 2023
Primary completion
May 6, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Nektar TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for screening, an Induction Period of 16 weeks, a Maintenance Period from Week 16-Week 52, and a Posttreatment Follow-Up Period for an additional year up to approximately Week 104 for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for the maintenance therapy period.
Conditions
- Moderate to Severe Atopic Dermatitis
Interventions
RezpegaldesleukinDrug
Pharmaceutical form: Injection solution Route of administration: subcutaneous
PlaceboDrug
Pharmaceutical form: Injection solution Route of administration: subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percent change in the Eczema Area and Severity Index (EASI) from baseline at Week 16Time frame: Week 0 and Week 16
Locations
107 sites in 10 countries. Site status is shown where the registry gives one.
Nektar Investigative Site
Bryant, Arkansas
Nektar Investigative Site
Fountain Valley, California
Nektar Investigative Site
Los Angeles, California
Nektar Investigative Site
Los Angeles, California
Nektar Investigative Site
Los Angeles, California
Nektar Investigative Site
Santa Monica, California
Nektar Investigative Site
Hialeah, Florida
Nektar Investigative Site
Hollywood, Florida
Nektar Investigative Site
Miami, Florida
Nektar Investigative Site
Miami Lakes, Florida
Nektar Investigative Site
St. Petersburg, Florida
Nektar Investigative Site
Tampa, Florida
Nektar Investigative Site
Marietta, Georgia
Nektar Investigative Site
Clarksville, Indiana
Nektar Investigative Site
Indianapolis, Indiana
Nektar Investigative Site
Louisville, Kentucky
Nektar Investigative Site
Flint, Michigan
Nektar Investigative Site
Troy, Michigan
Nektar Investigative Site
Las Vegas, Nevada
Nektar Investigative Site
New York, New York
Nektar Investigative Site
Fairborn, Ohio
Nektar Investigative Site
Mayfield Heights, Ohio
Nektar Investigative Site
Murfreesboro, Tennessee
Nektar Investigative Site
Bellaire, Texas
Nektar Investigative Site
Cypress, Texas
Nektar Investigative Site
Frisco, Texas
Nektar Investigative Site
Spokane, Washington
Nektar Investigative Site
Spokane, Washington
Nektar Investigative Site
Darlinghurst, New South Wales, Australia
Nektar Investigative Site
Kogarah, New South Wales, Australia
Nektar Investigative Site
Westmead, New South Wales, Australia
Nektar Investigative Site
Woolloongabba, Queensland, Australia
Nektar Investigative Site
Campbelltown, South Australia, Australia
Nektar Investigative Site
East Melbourne, Victoria, Australia
Nektar Investigative Site
Melbourne, Victoria, Australia
Nektar Investigative Site
Lovech, Bulgaria
Nektar Investigative Site
Pleven, Bulgaria
Nektar Investigative Site
Sofia, Bulgaria
Nektar Investigative Site
Sofia, Bulgaria
Nektar Investigative Site
Sevlievo, Gabrovo, Bulgaria
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.